Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination
Heptares and AstraZeneca: Combining forces in novel approach to drug discovery
An IMED Collaboration Update
When AstraZeneca was looking for alternative approaches to finding compounds for some particularly difficult targets, we teamed up with UK biotech Heptares Therapeutics. Heptares uses its proprietary Stabilised Receptor or StaR® technology to enable the techniques of structure-based and fragment-based drug discovery to be applied to difficult GPCR targets that our scientists have nominated. By combining our expertise, technologies and capabilities, this collaboration allows for a novel way of finding hits that we would otherwise not have been able to do, in order to bring new medicines to people who need them.Download collaboration update (PDF 337kb)
All Directors are collectively responsible for the success of AstraZeneca. Discover general information, images and biographies of our Board of Directors.
AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.
Path to new medicines
The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.
Visit our dedicated neuroscience site for more information on our research and partnering in the area.
Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines